Disease | vascular disease |
Phenotype | |diabetes |
Sentences | 529 |
PubMedID- 22508698 | Primary and secondary prevention of cardiovascular disease in diabetes with aspirin. |
PubMedID- 22798707 | In diabetes mellitus complicated by cardiovascular disease, insulin resistance and abnormal blood lipid concentrations play an important role. |
PubMedID- 24616778 | (6) attempted to demonstrate direct causation by examining cardiac innervation using metaiodobenzylguanidine imaging in patients with diabetes and no history of cardiovascular disease. |
PubMedID- 21700920 | Identifying and removing barriers to physical activity is important because of the strong relationship between physical inactivity and cardiovascular disease in people with type 2 diabetes and the likely cardiovascular benefits for people with type 1 diabetes (5,6). |
PubMedID- 25927959 | Background: hyperglycemia has been recognized as a primary factor in endothelial barrier dysfunction and in the development of micro- and macrovascular diseases associated with diabetes, but the underlying biochemical mechanisms remain elusive. |
PubMedID- 24627825 | Statin for the primary prevention of cardiovascular disease in patients with diabetes mellitus. |
PubMedID- 25554536 | Effect of statin therapy on incident type 2 diabetes mellitus in patients with clinically manifest vascular disease. |
PubMedID- 25612994 | We describe a concurrent manifestation of emphysematous pyelonephritis and ischaemic colitis in a 51-year-old diabetic woman and conclude that the colitis was due to pressure from a large retroperitoneal mass and sepsis complications combined with underlying peripheral vascular disease because of diabetes mellitus and hypertension. |
PubMedID- 21359028 | [28] although the metabolic syndrome unequivocally predisposes to type 2 diabetes mellitus,[29] many investigators of cardiovascular diseases consider this syndrome a multidimensional risk factor for ascvd. |
PubMedID- 23166795 | Observational study of the association of first insulin type in uncontrolled type 2 diabetes with macrovascular and microvascular disease. |
PubMedID- 26251229 | Using an interrupted time series design and segmented regression, we estimated changes in monthly prescribing rates for thiazolidinediones among all and prevalent diabetes patients with and without cardiovascular disease history (cv history). |
PubMedID- 25874615 | Pre-diabetes is somewhat predictive of macrovascular diseases, but most of this association seems to be mediated through mets [4–6]. |
PubMedID- 25298426 | These findings demonstrate that glp-1 as well as its analogs (glp-1-related reagents) may hold therapeutic potential in the treatment of diabetes with cardiovascular disease. |
PubMedID- 25685383 | Trends in the risk for cardiovascular disease among adults with diabetes in oman. |
PubMedID- 23900314 | Objectives: to provide a systematic and quantitative summary of the association between severe hypoglycaemia and risk of cardiovascular disease in people with type 2 diabetes and to examine the sensitivity of the association to possible uncontrolled confounding by unmeasured comorbid severe illness using a bias analysis. |
PubMedID- 26083376 | Pioglitazone has shown to have beneficial effect on cardiovascular diseases in patients with type 2 diabetes mellitus [18–20]. |
PubMedID- 25621136 | The combination therapy of ppar-α and ppar-γ agonists led to a decrease in ldl-c levels, and might be of benefit in the treatment of type 2 diabetes patients with cardiovascular disease by downregulating cytokines37. |
PubMedID- 26175995 | Postprandial hyperglycemia performs the important function in the development of type 2 diabetes and complications associated with cardiovascular diseases. |
PubMedID- 26177960 | In contrast with the severe systemic vascular disease associated with diabetes, clinically relevant pulmonary vascular disease is uncommon in diabetics. |
PubMedID- 22665334 | As an example, cpgs for cardiovascular diseases in diabetes mellitus have been developed.24 these cpgs contain detailed practical instructions for management of cardiovascular diseases in diabetic patients.24 some studies have reported that cpgs can improve the health outcomes of patients in terms of in-hospital mortality or los and concluded that cpgs were a significant independent predictor of clinical outcomes of patients.25,26 therefore, we think that the preparation and institution of cpgs for bleeding peptic ulcers with comorbid diabetes mellitus would be a promising policy implementation for improving the short-term clinical outcomes of these patients. |
PubMedID- 22994452 | Regarding cardiovascular mortality, age, diabetes mellitus, history of cardiovascular disease, lvmi, lvef, cimt, and pwv were significant predictors (table2). |
PubMedID- 21109113 | Erectile dysfunction and later cardiovascular disease in men with type 2 diabetes: prospective cohort study based on the advance (action in diabetes and vascular disease: preterax and diamicron modified-release controlled evaluation) trial. |
PubMedID- 26257973 | This disorder is a rare complication of poorly controlled diabetes, usually occurring in patients with preexisting microvascular disease. |
PubMedID- 24708826 | **p-value from adjusted regression model where group was recognised and not recognised; adjusted variables were age, apache ii score, hypertension, diabetes and any type of vascular disease (reduced to two principal components in regression models). |
PubMedID- 20195771 | diabetes also is associated with microvascular disease and autonomic neuropathy; and, these non-coronary atherosclerotic pathophysiologic processes also have the potential to increase the risk of sca. |
PubMedID- 24255692 | Atorvastatin use may also result in the primary prevention of cardiovascular disease in patients with type ii diabetes (3). |
PubMedID- 21517955 | Post-meal hyperglycaemia is considered a risk factor for cardiovascular disease in patients with type 2 diabetes [1]. |
PubMedID- 23755276 | Chronic hyperglycemia in diabetes is associated with cardiovascular disease and microvascular pathologies in the retina, kidney and peripheral nerves [1], [2]. |
PubMedID- 26100640 | Nobody disputes the fact that type 1 diabetes increases the risk of death from cardiovascular diseases. |
PubMedID- 24102059 | Further data adjustment for age, gender, diabetes status, and history of past cardiovascular disease, dialysis vintage, and fmi did not substantially affect these results (table 5). |
PubMedID- 20855550 | Additionally, in order to reduce the high risk of cardiovascular disease in people with diabetes (24), a greater use of aspirin (1) has been encouraged. |
PubMedID- 25923078 | Type 2 diabetes mellitus patients with cardiovascular disease showed higher expression of plasma retinol binding protein and glutathione peroxidase-3 compared to those without cardiovascular disease and non-diabetic controls. |
PubMedID- 26481300 | Book review: diabetes in cardiovascular disease: a companion to braunwald's heart disease. |
PubMedID- 24369540 | Until now, most common additive risk factors for vascular disease in people with diabetes have been demonstrated as hyperglycaemia, insulin resistance, dyslipidaemia, hypertension, tobacco use, and obesity [2, 5]; however, the interaction of the factors and molecular signalling pathways have not been fully elucidated. |
PubMedID- 25328404 | Aim/introduction: circulating levels of n-terminal fragment of probrain natriuretic peptide (nt-probnp) are established as a risk factor for cardiovascular disease and mortality in patients with diabetes, as well as in the general population. |
PubMedID- 23564913 | In previous studies, statin therapy has been associated with a 19–55% reduction in cardiovascular disease events in patients with diabetes (33). |
PubMedID- 26292807 | Patients’ characteristics including metabolic co-morbidities and leucocyte counts as well as treatment characteristics are summarized in table 1. comorbidities included diabetes in 15.1 % of patients, cardiovascular disease in 34.6 % and hypertension in 45.7 %. |
PubMedID- 25214836 | Left ventricular hypertrophy (lvh) and albuminuria are both markers for cardiovascular diseases (cvds) in patients with type 2 diabetes mellitus (t2dm). |
PubMedID- 26383851 | [54] in taiwan, where they found a higher prevalence of vascular diseases associated with diabetes in females than in males. |
PubMedID- 26473035 | Moreover, microalbuminuria is associated with cardiovascular disease in patients with diabetes mellitus [7] and in the general population [8]. |
PubMedID- 24049653 | It was determined in many multiple independent longitudinal studies that the hp genotype is an independent determinant of the risk of incident cardiovascular disease in individuals with diabetes mellitus (dm) [146–151]. |
PubMedID- 24404539 | Clinically diagnosed diabetes mellitus with cardiovascular disease (dm+cvd) shall be the endpoint. |
PubMedID- 20920303 | If hypertension and chronic renal disease co-exist, as is common in patients with diabetes mellitus, the risk of cardiovascular disease is heightened. |
PubMedID- 26318399 | Association between cetp gene polymorphism, insulin resistance and risk of diabetes mellitus in patients with vascular disease. |
PubMedID- 22389337 | Since diabetes increases the risk of cardiovascular disease, for example, the impact of interventions for the treatment of hyperglycaemia in reducing this risk should be assessed. |
PubMedID- 24476202 | Participants with type 2 diabetes were free of clinical evidence of cardiovascular disease and renal involvement. |
PubMedID- 22347652 | The mechanisms underlying the increased risk of cardiovascular disease associated with diabetes mellitus (dm) are not fully defined. |
PubMedID- 22194960 | Individuals with pre-diabetes often bear clusters of cardiovascular disease risk factors [1]. |
PubMedID- 20601395 | Methods and results: one hundred and fifty type 2 diabetes patients with cardiovascular disease (cvd) or >/= 1 other cvd risk factor were randomized to receive rosiglitazone vs. |
PubMedID- 24654672 | Whilst the number of deaths as a result of ketoacidosis or severe hypoglycaemia is lower than for cardiovascular disease in people with type 1 diabetes, these acute metabolic decompensations cause 9–13% of deaths in adults 1,2, with a higher proportion of 20–44% of deaths in children and young adults (excluding ketoacidosis at diagnosis) 1–5. |